Moolec Science (MLEC) Gross Margin (2023 - 2024)
Moolec Science (MLEC) reported Gross Margin of 25.52% for Q4 2024, down 11757.0% on a YoY basis from N/an in Q1 2024, and down 2789.22% sequentially from 0.95% in Q3 2024.
Moolec Science (MLEC) Gross Margin (2023 - 2024) Analysis & Trends
Moolec Science (MLEC) has 2 years of Gross Margin data on file, last reported at 25.52% in Q4 2024.
- For the quarter ending Q4 2024, Gross Margin fell 11757.0% year-over-year to 25.52%; the trailing twelve-month figure through Dec 2024 stood at 8.16% (changed N/A YoY), and the FY2024 full-year result was 8.4%, up 2424.0% from the prior year.
- Gross Margin fell to 25.52% in Q4 2024, from 0.95% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 92.05% in Q4 2023 to a low of 25.52% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 88.95% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Moolec Science | 5.35 Bn | 5.35 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -25.52% |
| Sep 30, 2024 | 0.95% |
| Jun 30, 2024 | -4.70% |
| Mar 31, 2024 | 4.35% |
| Dec 31, 2023 | 92.05% |
| Sep 30, 2023 | 12.67% |